Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

New Analysis of SPIRIT II and SPIRIT III Data Confirms Patients Treated with XIENCE V Are at Lower Risk of Experiencing Death, a Heart Attack or a

Repeat Procedure Compared to TAXUS(R) at Two Years

WASHINGTON, Oct. 13 /PRNewswire-FirstCall/ -- Data from an independent meta-analysis of Abbott's SPIRIT II and SPIRIT III randomized clinical trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary Stent System continues to deliver clinically significant benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary stent system out to two years. In this meta-analysis, which included patients from the United States, Europe and Asia-Pacific, XIENCE V demonstrated clinical superiority to TAXUS in the endpoints of target vessel failure (TVF) and major adverse cardiac events (MACE) at two years. XIENCE V also demonstrated significantly lower clinical events rates than TAXUS in the key efficacy (target lesion revascularization) and safety (cardiac death or heart attack) components of MACE at two years. The results are being presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, during the Cardiovascular Research Foundation's 20th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.

"The pooled results from the SPIRIT II and SPIRIT III trials demonstrate that XIENCE V is safer and provides greater efficacy than TAXUS at two years," said Dr. Stone, professor of medicine at Columbia University Medical Center and chairman, Cardiovascular Research Foundation, New York. "In the meta-analysis at two years, XIENCE V compared to TAXUS demonstrated statistically significant reductions in the combined measure of all-cause death or heart attack, as well as further reducing the need for repeat cardiac procedures -- reinforcing that XIENCE V is a true second-generation stent, which results in improved patient outcomes."

The meta-analysis of 1,302 patients from the SPIRIT I
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...FirstCall/ -- Virtual Health Technologies, Inc. (O...previously confirmed Letter of Intent to sell all ...hnologies, Inc (WNDM) is subject to final approval...GI. ,, Shareholder Assurances ,, "We bel...ream and cash realized from the transaction would ...
(Date:11/6/2009)...Call/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA ),...t of small-molecule therapeutics for the treatment...(HIV), today reported recent accomplishments and f...nths ended September 30, 2009. ,, (Logo: htt...O ) ,, "Since our last quarterly update, we hav...
(Date:11/6/2009)...ll/ -- Cyberonics, Inc. (Nasdaq: CYBX ) today ann...lts for the second quarter ended October 23, 2009 ...day, November 18, 2009 at 5:00 PM EST. The compan...results on Thursday, November 19, 2009 at 9:00 AM ...ts Conference Call Instructions ,, To listen ...
Breaking Medicine Technology:OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 2Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 3Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 4Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 5Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 6Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 7Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results 8Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 1Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 3MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 1MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 2MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 3MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 4MacuSight 28R 29 Provides Clinical Development Update for Perceiva 28TM 29 14292 5InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 1InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting 14290 2
(Date:11/6/2009)...ewswire/ -- Two additional large community H1N1 in...County Health Department, the department announced...ark in Sterling Heights Saturday, Nov. 14 and 21, ...4900 Metropolitan Parkway. At least 3,000 doses wi...inics. Both the nasal spray and injectable version...
(Date:11/6/2009)...nd arrests. ,, WASHINGTON, Nov. 6 /PRNewswire-...ncarcerated after being arrested at Pelosi,s offic... Father Norman Weslin, Missy Smith, Joan McKee, Ro...held at 2:00 P.M., 500 Indiana Ave Northwest. ,...o-life advocates will appear in Court after being ...
(Date:11/6/2009)...resident and CEO of the National Council on Aging:...-- The National Council on Aging urges the House t...(H.R. 3962), which we regard as a historic step to...lth care for Americans of all ages. ,, After a ...l is a good deal for America,s seniors. H.R. 3962 ...
(Date:11/6/2009)...e/ -- A recent special supplement to the Journal o...country,s pressing need for a larger and fully cap...ten by the leading academic voices in public healt...ns (LWW), also sheds light on the challenges the U...s. LWW is part of Wolters Kluwer Health, a leading...
(Date:11/6/2009)...e following statement in observance of Pancreatic ...PRNewswire-USNewswire/ -- "Pancreatic cancer is a ...leading cause of death by cancer in the United Sta... diagnosed with the disease and more than 35,000 w..., "To find a cure for pancreatic cancer researche...
Breaking Medicine News(10 mins):Health News:Macomb County Announces Two Additional Communitywide H1N1 Flu Vaccine Clinics Saturday, Nov. 14 and 21; Clinic For Health Care Workers Only Set For Nov. 12 2Health News:NCOA Supports H.R. 3962, the Affordable Health Care for America Act 2Health News:Journal of Public Health Management & Practice Calls for Growth in Public Health Workforce 2Health News:Journal of Public Health Management & Practice Calls for Growth in Public Health Workforce 3
...sts have shown that eating curry helps enhances me...’s.// In a research conducted by National Uni... people aged between 60 and 93 not suffering from ...r had it or had it rarely. Dr. Tze-Pin Ng, ...
...million new cases of skin cancer will be diagnosed...rly, this potentially deadly //condition is extrem.... While current treatments for skin cancer involve...g today at ACADEMY ’06, the American Academy of De...
...ampian voted for the closure of maternity services...pectant mothers and their unborn babies have been ...st will be left with only three fully dedicated ma...s to Aberdeen Maternity Hospital. The decision...
... emergency life saving operation by writing a no g...It was reported that Roy, 77, was warned that the ... and he knew that there was no way he could afford... get bounced his life would have been saved, by th...
...ng over a report suggesting that legal changes be ...progeny through embryo selection.// Sex- sel...is prohibited in New Zealand, Britain and most of ...s, such as deafness, to be passed on to their chil...
...a by Johns Hopkins Bloomberg School of Public Heal...s the possibility of early death// for their child...ing perinatal and neonatal stages for children of ...indings indicate that almost 1 in 5 perinatal and ...
Other Medicine News:Health News:Emerging Therapies for Skin Cancer Treatment 2Health News:Emerging Therapies for Skin Cancer Treatment 3Health News:Emerging Therapies for Skin Cancer Treatment 4Health News:Closures of Maternity Units across Grampian Arouses Concern 2Health News:Wily Old Man Undergoes A life Saving Operation With A Worthless Cheque 2Health News:Parental Role In Embryo-Selection Urged 2Health News:Risk Of Death Increased In Children Of Mothers Subjected To Domestic Violence 2
SureSigns VS1 Vital Signs Monitor
... continuous monitoring, the M3 and M4 monitors off...onatal patient care. M Series monitors are equippe...basic set of non-invasive parameters and input for...Measurement Server extensions offer Mainstream or ...
...lp (OLEH), an interactive electronic textbook, pro...ted information. OLEH brings clinical decision sup...ost right on the patient monitor screen while tak... reduction and greater efficiencies with practical...
MP30
Medicine Products: